4D Molecular Therapeutics FDMT delivered earnings and revenue surprises of -3.85 and 18.77 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Why Is 4D Molecular Therapeutics, Inc. (FDMT) Stock Down Today?
Updated Nov 16, 2026 8:00 PM ET · Prev Close $12.23
Primary Move Catalyst & Conviction
65% Signal ConvictionBiotechnology & Biological Products sector moving together
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Market & Sector Relative Strength
FDMT lagging the S&P 500 by -2.85%Options Flow & Execution Desk
Neutral Flow · P/C 0.77Unlock 1 Unusual FDMT Options Sweep Strike
See exact institutional strike concentrations, volume-to-OI ratios, and multi-leg payoff blueprints with Tradestie Pro.
Recent FDMT Catalyst Headlines
Verified Wire4D Molecular Therapeutics FDMT may benefit from upcoming phase 3 data for a competing gene therapy
Emeryville, Calif., Nov. 13, 2026 Globe Newswire -- 4D Molecular Therapeutics Nasdaq Fdmt, 4DMT or the Company , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potenti
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respecti
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $11.65
Technical Regime (FDMT)
BEARISH MA TREND1-Year Historical Move Analogs
58 EventsSessions in the past year where FDMT moved >3.0% down:
Retail & Crowd Sentiment
Quiet4DMT completes enrollment for 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD, over-enrolled and ahead of schedule, with data expected in H2 2027.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes...
Get Instant FDMT Catalyst Alerts
Receive an email alert when FDMT triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversFDMT Session & Catalyst FAQ
Why is FDMT stock down today?
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Is FDMT stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.38x relative volume (low participation). Our multi-factor model currently rates FDMT as HOLD. Review full valuation, quality, and timing signals on the FDMT Buy or Sell Decision Brief →
What is FDMT's intrinsic value and expected trading range?
At $11.65, FDMT's modeled 1-to-3 session range is $11.30 – $11.88, with a key inflection level at $11.07 (support). Compare current price against multi-year cash flow projections in the FDMT Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for FDMT?
RSI at 46.9 reflects soft below-midline momentum. FDMT trades at $11.65 relative to its 20-day SMA ($12.12) and 50-day SMA ($13.08), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.